DisCoVering potential candidates of RNAi-based therapy for COVID-19 using computational methods

Area of Science:

• Virology
• Bioinformatics
• Computational Biology

Background:

• The SARS-CoV-2 pandemic necessitates rapid development of effective treatments.
• Traditional experimental methods for drug discovery are time-consuming.
• Computational approaches offer a faster way to screen potential therapeutic candidates.

Purpose of the Study:

• To computationally identify RNA interference (RNAi) strategies targeting conserved regions of the SARS-CoV-2 genome.
• To discover microRNAs (miRNAs) and small interfering RNAs (siRNAs) with high efficacy and low human side effects for antiviral therapy.

Main Methods:

• Utilized computational and bioinformatic analyses to investigate RNAi-based therapies.
• Analyzed conserved regions of the SARS-CoV-2 genome for target identification.
• Screened human, bat, and other species' miRNAs for potential antiviral activity.
• Designed novel, target-specific siRNAs against conserved SARS-CoV-2 sequences.

Main Results:

• Identified a small set of promising miRNAs with potential antiviral properties.
• Designed five specific siRNAs with high predicted affinity to the SARS-CoV-2 genome.
• The selected candidates demonstrated potential for low side effects in humans.

Conclusions:

• Computational screening identified promising miRNA and siRNA candidates for SARS-CoV-2 RNAi therapy.
• These candidates show potential for rapid experimental validation, accelerating treatment design.
• The study provides a foundation for developing novel antiviral strategies against SARS-CoV-2.